US Patent Issued to Novartis on Aug. 25 for "Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins" (Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,714,739, issued on Aug. 25, was assigned to Novartis AG (Basel, Switzerland).

"Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant fc fusion proteins" was invented by John Louis Diener (Cambridge, Mass.), Jiaping Gao (Ashland, Mass.) and Rick Jerome Schiebinger (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to the identification of new therapeutic methods for the FGF21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. insulin receptor mutation disorders (INSR disorders) and...